RNTX

Rein Therapeutics Inc

RNTX.US reintx.com + Research + Basket
CIK 0001420565
Employees 10
Phone 737 802 1989
Fiscal year end December
IPO Mar 12, 1986
Address 12407 N. Mopac Expy., Austin, TX, United States, 78758
0.61
-0.05 (-7.09%)
USD · NASDAQ
52-week range
0.54
2.10
Trading at 5% of the 52-week range
Market Cap
52.80M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
0.12
Div. Yield
N/A
% Institutions
52.41%
% Insiders
5.02%

1 Year

-61.5%

3 Year

-60.3%

10 Year

-99.7%
Description

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.

Actions

Add an action for RNTX.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. James Brian Windsor Ph.D. CEO, President & Director 1966
Mr. Timothy M. Cunningham CPA, M.B.A. Interim CFO & Principal Accounting Officer 1962
Dr. Cory M. Hogaboam Ph.D. Chief Scientific Officer NA
Ms. Jennifer Faigle Counsel NA
Mr. Ron Chen VP of Finance and Corporate Controller NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Nov 14, 2025 Voss Capital, Lp N/A Purchase 104.18K $1.22 $127.10K SEC
Oct 28, 2025 Voss Capital, Lp N/A Purchase 178.39K $1.39 $247.96K SEC
Oct 27, 2025 Voss Capital, Lp N/A Purchase 97.48K $1.37 $133.55K SEC
Oct 24, 2025 Voss Capital, Lp N/A Purchase 30.18K $1.39 $41.94K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Voss Capital LLC 5.26M Jun 30, 2026 6.10% $0.25 19.91%
Cable Car Capital LLC 5.20M Jun 30, 2026 6.02% $0.12 1,136.90%
ADAR1 Capital Management LLC 4.50M Jun 30, 2026 5.22% $0.21 0.00%
Vanguard Capital Management, LLC 3.38M Jun 30, 2026 3.92% $0.00 238.29%
BIOS CAPITAL MANAGEMENT, LP 2.98M Jun 30, 2026 3.46% $7.44 50.44%
Ikarian Capital, LLC 2.95M Jun 30, 2026 3.42% $0.33 0.00%
Great Point Partners LLC 2.58M Jun 30, 2026 2.98% $0.51 0.00%
Citadel Advisors Llc 2.44M Jun 30, 2026 2.83% $0.00 0.00%
Velan Capital Investment Management LP 1.70M Jun 30, 2026 1.97% $1.08 0.00%
RIMA MANAGEMENT, LLC 1.23M Jun 30, 2026 1.43% $0.04 433.10%
Prosight Management, LP 1.10M Jun 30, 2026 1.28% $0.20 167.25%
Bleichroeder LP 1.00M Jun 30, 2026 1.16% $0.19 0.00%
BOOTHBAY FUND MANAGEMENT, LLC 889.45K Jun 30, 2026 1.03% $0.01 0.00%
Geode Capital Management, LLC 733.14K Jun 30, 2026 0.85% $0.00 112.70%
University Of Texas Investment Mgmt Co 511.61K Jun 30, 2026 0.59% $0.06 0.00%
Vanguard Fiduciary Trust Co 382.52K Jun 30, 2026 0.44% $0.00 147.56%
State Street Corp 379.60K Jun 30, 2026 0.44% $0.00 400.11%
Empery Asset Management, LP 370.83K Jun 30, 2026 0.43% $0.45 0.00%
Palogic Value Management LP 360.00K Jun 30, 2026 0.42% $0.06 100.00%
Sigma Planning Corp 353.68K Jun 30, 2026 0.41% $0.01 1.43%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 2.52M 2.92% ▲ 0.00% Sep 30, 2026
2 Fidelity Extended Market Index 367.25K 0.43% ▼ 0.53% Aug 31, 2026
3 Fidelity Series Total Market Index 105.68K 0.12% ▲ 0.00% Aug 31, 2026
4 Fidelity Total Market Index 101.18K 0.12% ▲ 22.34% Aug 31, 2026
5 iShares Micro-Cap ETF 79.04K 0.09% ▲ 0.00% Oct 29, 2026
6 Fidelity Nasdaq Composite ETF 76.58K 0.09% ▲ 0.00% Oct 29, 2026
7 Vanguard U.S. Eq Idx £ Acc 50.99K 0.06% ▲ 299.18% Sep 30, 2026
8 Vanguard Balanced Index Inv 43.37K 0.05% ▲ 0.00% Sep 30, 2026
9 1290 VT Micro Cap K 5.74K 0.01% ▲ 0.00% Aug 31, 2026

Financial Highlights

▼
Market Cap: $52.80M
EBITDA: $-20.76M
Book Value: $0.12
Earnings/Share: $-1.68
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -21.02%
ROE (TTM): -96.42%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $58.36M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 86.27M
Shares Float: 66.11M
% Insiders: 5.02%
% Institutions: 52.41%
Shares Short: 590.76K
Shares Short (Prior Month): 651.18K
Short Ratio: 1.39
Short % Float: 0.69%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-1.00K
Gross Profit
subtotal
$-1.00K
SG&A
adjust
$-10.90M
R&D
adjust
$-11.03M
Operating Income
subtotal
$-21.93M
Other / Non-Operating Items
adjust
$-27.94M
Net Income
subtotal
$-49.87M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about RNTX.US!